Second-quarter 2026 revenue rose 39% year-over-year to $959 million, driven by strong growth in INGREZZA, CRENESSITY, and the addition of VYKAT XR post-Soleno acquisition. Full-year INGREZZA sales guidance was raised, and new clinical milestones are expected in 2027.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.